ACM
ALXN

AlphaCrest Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

AlphaCrest Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,600
Closed -$210K – 1380
2019
Q2 		$210K Sell
1,600
-888
-36% -$114K 0.02% 960
2019
Q1 		$336K Sell
2,488
-9,712
-80% -$1.21M 0.05% 610
2018
Q4 		$1.19M Buy
+12,200
New +$1.44M 0.35% 37

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AlphaCrest Capital Management's ALXN Position: Q3 2019 in Review

AlphaCrest Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 1,600 shares — an estimated $210K sold.

AlphaCrest Capital Management first reported a position in ALXN in Q4 2018 and held it in 3 quarters. The position peaked at $1.19M in Q4 2018. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • AlphaCrest Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 1,600 Alexion Pharmaceuticals shares in Q3 2019, an estimated $210K.
  • AlphaCrest Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • AlphaCrest Capital Management's Alexion Pharmaceuticals position peaked at $1.19M in Q4 2018.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on AlphaCrest Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.